Alongside metformin, the new antidiabetic non-insulin drugs, namely, SGLT-2is and GLP-1 RAs, are safe for the treatment of patients with T2DM in a standard-of-care regimen with maximum tolerated doses, even if they are combined with other drugs that are used for the treatment of HBP, respectively, BB, CCB, ACEI, or ARB, or with drugs for the treatment of dyslipidemia, such asstatins, or when administered simultaneously with other antidiabetic drugs such as metformin. Here, GCG is linked to metabolic syndrome.